A new endogenous immunoenzyme assay for prostatic acid phosphatase evaluated

Area of Science:

• Clinical Chemistry
• Immunoassays
• Enzyme Assays

Background:

• Prostatic acid phosphatase (PAP) is a biomarker for prostate cancer.
• Accurate and sensitive assays are crucial for clinical diagnosis and monitoring.

Purpose of the Study:

• To evaluate the performance of the "ORTHO PAP-IA," a novel endogenous immunoenzyme assay for prostatic acid phosphatase (PAP).
• To assess the assay's sensitivity, reliability, and correlation with existing methods.

Main Methods:

• The assay utilizes a double-antibody precipitation technique for antigen capture.
• Quantification is achieved through a highly sensitive colorimetric reaction measuring enzymic activity.
• Antibodies are used in large excess to enhance reaction speed and assay robustness.

Main Results:

• The analytical sensitivity of the ORTHO PAP-IA exceeds that of radioimmunoassay.
• Linearity of absorbance was observed up to 4.0, requiring only a single calibration standard.
• Excellent precision was demonstrated with within-run coefficients of variation (CV) <2% and between-run CV ~4%.

Conclusions:

• The ORTHO PAP-IA is a sensitive, precise, and reliable assay for prostatic acid phosphatase.
• The assay's performance, including strong correlation (r=0.993) with radioimmunoassay, supports its clinical utility.
• The assay simplifies procedures by not requiring individual blanks or duplicate assays.